Atjaunināt sīkdatņu piekrišanu

E-grāmata: Multiregional Clinical Trials for Simultaneous Global New Drug Development

Edited by (SanofiAventis, Bridgewater, New Jersey, USA), Edited by (Sanofi Pasteur, Swiftwater, Pennsylvania, USA)
  • Formāts - EPUB+DRM
  • Cena: 57,60 €*
  • * ši ir gala cena, t.i., netiek piemērotas nekādas papildus atlaides
  • Ielikt grozā
  • Pievienot vēlmju sarakstam
  • Šī e-grāmata paredzēta tikai personīgai lietošanai. E-grāmatas nav iespējams atgriezt un nauda par iegādātajām e-grāmatām netiek atmaksāta.

DRM restrictions

  • Kopēšana (kopēt/ievietot):

    nav atļauts

  • Drukāšana:

    nav atļauts

  • Lietošana:

    Digitālo tiesību pārvaldība (Digital Rights Management (DRM))
    Izdevējs ir piegādājis šo grāmatu šifrētā veidā, kas nozīmē, ka jums ir jāinstalē bezmaksas programmatūra, lai to atbloķētu un lasītu. Lai lasītu šo e-grāmatu, jums ir jāizveido Adobe ID. Vairāk informācijas šeit. E-grāmatu var lasīt un lejupielādēt līdz 6 ierīcēm (vienam lietotājam ar vienu un to pašu Adobe ID).

    Nepieciešamā programmatūra
    Lai lasītu šo e-grāmatu mobilajā ierīcē (tālrunī vai planšetdatorā), jums būs jāinstalē šī bezmaksas lietotne: PocketBook Reader (iOS / Android)

    Lai lejupielādētu un lasītu šo e-grāmatu datorā vai Mac datorā, jums ir nepieciešamid Adobe Digital Editions (šī ir bezmaksas lietotne, kas īpaši izstrādāta e-grāmatām. Tā nav tas pats, kas Adobe Reader, kas, iespējams, jau ir jūsu datorā.)

    Jūs nevarat lasīt šo e-grāmatu, izmantojot Amazon Kindle.

In a global clinical development strategy, multiregional clinical trials (MRCTs) are vital in the development of innovative medicines. Multiregional Clinical Trials for Simultaneous Global New Drug Development presents a comprehensive overview on the current status of conducting MRCTs in clinical development. International experts from academia, industry, and health organizations address various aspects of the important problems in global clinical development and MRCTs.

The book first provides a high-level introduction to the context, motivation, opportunities, and challenges in simultaneous global clinical development using MRCTs. It then focuses on the design, monitoring, and analysis/interpretation of MRCTs. The book concludes with an examination of the latest research topics from MRCT perspectives, such as special considerations by local health authorities, health economic evaluations, benefit-risk assessment, and medical devices.

Explaining how to design, conduct, and interpret MRCTs, this book will help biostatisticians working in the late-stage clinical development of medical products. It will also be useful for statisticians and clinicians in the biopharmaceutical industry, regulatory agencies, and medical research institutes.

Recenzijas

This book consolidates current state of knowledge regarding relevant topics on MRCTs (design, operation, and analysis/interpretation) into well-organized chapters. This book should serve as a useful source of information to anyone who plans to work or is working on MRCTs. There are many on-going challenges and we also hope it will stimulate further research in MRCTs. ~Nobushige Matsuoka, PhD and Norisuke Kawai, PhD, Pfizer Japan Inc.

" . . . Contributors to this book are among the best experts in their corresponding fields. . . Most chapters are short, with about 20 pages including references. This length of chapter makes the book easy to read and easy to follow. Concepts involving design, conduct, and analysis of MRCT are not simple, but this book successfully presents all of these topicssetting the stage and drilling down to a reasonable depth, without unnecessary detail. It also introduces many real world examples to help readers understand some of the difficult concepts. . . Each chapter introduces a stand-alone, self-contained topic. Cross-referencing of chapters is rarely needed, but is provided where appropriate. I learned a lot from this book, especially that issues arising in MRCT are much more difficult than issues in multi-center trials, from which much of my experience with clinical trials comes." ~Naitee Ting, Boehringer Ingelheim Pharmaceuticals, Inc.

"The editors have collected chapters and sections contributed by many authors, with each addressing a different important problem in global clinical development and MRCTs. The contributions to individual topics from academia, industry, and health authorities around the globe, strengthen the documentation greatly . . . I fully endorse the views of the editors that biostatisticians working in the area of randomized controlled trials in general, and MRCTs in particular, will find this book a useful reference." ~Sada Nand Dwivedi, International So

Preface xiii
Acknowledgments xv
Editors xvii
Contributors xix
Section I Simultaneous Global Development
1 The Journey to Multiregional Clinical Trials in Support of Simultaneous Global Product Development
3(12)
Christy Chuang-Stein
2 General Principles and Considerations in Multiregional Clinical Trials for Simultaneous Global New Drug Development
15(16)
Ekopimo Ibia
Bruce Binkowitz
3 Bridging Studies versus Multiregional Trials
31(10)
Weichung J. Shih
Section II Multiregional Clinical Trial: Design Considerations
4 Multiregional Clinical Trials: Assessing Consistency of Treatment Effect
41(12)
Joshua Chen
Hongwei Wang
5 Regulatory Perspectives: Different Requirements/Endpoints and Needs for Harmonization
53(6)
Cynthia J. Girman
Bruce Binkowitz
6 Intrinsic and Extrinsic Factors and Rationales to Be Considered When Defining Regions
59(18)
Yoko Tanaka
7 Models and Sample Sizes for Multiregional Clinical Trials
77(10)
Hui Quan
Mingyu Li
8 Multiregional Clinical Trials in Oncology Drug Development
87(14)
Mingxiu Hu
9 A Few More Considerations in Multiregional Clinical Trials on Regional Differences
101(12)
Bo Yang
Yijie Zhou
10 Optimal Multiregional Clinical Trials
113(18)
Zhaoyang Teng
Mark Chang
11 Implementation of Multiregional Clinical Trial Design
131(20)
Xuezhou Mao
Mingyu Li
Section III Multiregional Clinical Trial: Data Monitoring Committee and Monitoring Regional Differences
12 Independent Data Monitoring Committees in Multiregional Clinical Trials
151(16)
Janet Wittes
13 Monitoring Regional Differences Based on Blinded Data in Multiregional Clinical Trials
167(10)
Joshua Chen
14 Adaptive Multiregional Clinical Trials
177(18)
Zhaoyang Teng
Mark Chang
Section IV Multiregional Clinical Trial: Analysis, Reporting, and Interpretation
15 Lessons Learned and Recommendations Regarding Multiregional Clinical Trials from a Well-Practiced Industry Statistician
195(8)
Bruce Binkowitz
16 Quantification of Regional Treatment Effects for Multiregional Clinical Trials
203(12)
Hui Quan
Xuezhou Mao
17 Multiregional Clinical Trials: Country-Specific Assessment
215(12)
Joshua Chen
Xuezhou Mao
18 Multiregional Outcome Trial for a Multivalent Human Papillomavirus Vaccine: A Case Study
227(18)
Oliver M. Bautista
Erin Moeller
Alain Luxembourg
Section V Multiregional Clinical Trial: Latest Development and Trends
19 The Discrete Random-Effects Model---Assessing Benefit and Consistency of Treatment Effect
245(14)
Hsiao-Hui Tsou
K. K. Gordon Lan
Jung-Tzu Liu
Chin-Fu Hsiao
20 New Drug Development Paradigms in China: Simultaneous Global Drug Development Program
259(14)
Gang Chen
Qin Huang
Frank Shen
Zhilong Yuan
Dayao Zhao
21 Special Considerations for Emerging Markets
273(8)
Gang Li
Jun Zhao
22 A Predictive Bayesian Approach to the Design and Analysis of Bridging Studies
281(12)
A. Lawrence Gould
William W. B. Wang
23 Multiregional Clinical Trial: A Japanese Viewpoint
293(8)
Madoka Takeuchi
Masahiro Takeuchi
24 Special Considerations for Medical Devices: An Overview
301(12)
Yunling Xu
Nelson Lu
Gerry Gray
25 Use of Multinational Randomized Clinical Trials in Economic Evaluations of Health Care
313(18)
Joseph Heyse
Jieling Chen
John R. Cook
26 Regional Benefit and Risk Evaluations
331(12)
Soo Peter Ouyang
Hui Quan
Index 343
Joshua Chen is the global head of biostatistics and programming at Sanofi Pasteur. He previously worked on clinical development of small molecules, biologics, and vaccines at Merck Research Laboratories. His experience spans many therapeutic areas with a major focus on human vaccines and antiviral drugs. He has extensive experience in the study, design, conducting, and reporting of international clinical trials from proof of concept through regulatory approvals and life cycle management. His primary research interest is clinical trial designs, including group sequential methods, adaptive designs, and multiregional clinical trials (MRCTs). Dr. Chen was a colead of the cross-industry MRCT Consistency Working Group under PhRMA (20082011) and the Society for Clinical Trials (20122014). He earned his PhD in statistics from the University of WisconsinMadison.

Hui Quan is an associate vice president and global head of the methodology group in the Biostatistics and Programming Department of SanofiAventis. A fellow of the American Statistical Association, he has 24 years of pharmaceutical industry experience in many therapeutic areas ranging from early phase to phase IV studies. He has published 82 papers, including 59 statistical papers. His research interests include multivariate analysis, safety analysis, multiplicity adjustment, missing handling, adaptive design, integrated data analysis, modeling and simulation, benefit/risk assessment, and MRCTs. Dr. Quan was a colead of the MRCT Consistency Assessment Working Group under PhRMA (20082011) and the Society for Clinical Trials (20122014). He earned his PhD in statistics from Columbia University.